Idelalisib Active Not Recruiting Phase 3 Trials for Chronic Lymphocytic Leukaemia (CLL) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01569295A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT02970318A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL